Abstract
MO2-2 Post-marketing observational safety study of durvalumab in Japanese patients with unresectable stage III NSCLC (PACIFIC regimen)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/j.annonc.2023.09.153
Journal: Annals of Oncology | Publication Date: Nov 1, 2023 |
MO2-2 Post-marketing observational safety study of durvalumab in Japanese patients with unresectable stage III NSCLC (PACIFIC regimen)
Join us for a 30 min session where you can share your feedback and ask us any queries you have